Why the study?
Excessive locomotor muscle group III/IV afferent feedback has been suggested to underlie exercise intolerance in HFrEF, but had never been investigated in human heart failure.
Does lumbar intrathecal fentanyl improve peak exercise capacity and cardiac output in patients with HFrEF?
Does lumbar intrathecal fentanyl improve peak exercise capacity and cardiac output in patients with HFrEF?
Inhibition of locomotor muscle group III/IV afferents via intrathecal fentanyl improves exercise capacity and cardiac output in HFrEF patients by reducing systemic vascular resistance.
No takes yet. Share an insight, caveat, or question.
First human data on group III/IV afferents in HFrEF exercise intolerance; leaves open whether targeting this feedback improves capacity.
Smith et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: